AONC American Oncology Network, Inc.: Operating Margin

Symbol and logo of brand American Oncology Network Inc (AONC)

The biomedicine sector remains resilient due to its humanitarian status and neutrality in global conflicts. Operational efficiency dynamics demonstrate a pricing vector with a metric value of -3.80. American Oncology Network (AONC) relies on a high-tech ecosystem for private physicians, providing access to analytics. Meanwhile, the company retains specialists by adhering to ethical standards and granting broad autonomy in medical practice.

AONC: AON Operating Margin 02/21/2024 - 08/04/2024

AON - analytical breakdowns and key metrics (AONC)

- share price and consensus valuation forecast:
Fundamental company analysis:AONC, AON
Brand item of American Oncology Network Inc

Operating margin measures the share of profit from core business processes before financial expenses and taxes, reflecting the efficiency of cost management. For American Oncology Network (AONC), this metric characterizes the monetization of its network of partnerships with pharma behemoths and regional clinics, while the operating margin curve allows investors to determine the stage of profitability recovery and the risk of reaching a growth ceiling.

Competing companies

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|Operating Profit Rate ACTU|CTOR - Operating Profitability|Profitability of Operations tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operating Profitability|FATE: Operating Profit Ratio|WHWK (Aadi Bioscience, Inc.) - Operating Margin|TCRX (TScan Therapeutics) - Operating Profit Ratio|Operating Profitability Champions Oncology (CSBR)|Profitability of Operations XBiotech USA|Operating Profitability CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Operating Return on Sales|RADX - Operating Profitability|ARTV - Operating Margin|Adlai Nortye Ltd (ANL) - Operating Profitability|Veru Pharma - Operating Profit Rate|Operating Profitability Tempest Therapeutics Corp|Return on Sales by Operating Profit XLO (Xilio Therapeutics, Inc.)|Operating Margin RENB|MURA (Mural Oncology) - Operating Profit Rate|Operating Margin KAPA (Kairos Pharma Ltd)|OKUR: Return on Sales by Operating Profit|GDTC: Operating Sales Margin|CRIS - Operating Margin|APLM: Operating Margin|Operating Return on Sales tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Operating Margin|Operating Margin Genprex Inc.|Operating Margin CLDI|Operating Sales Margin Sunshine Biopharma, Inc. SBFM|Operating Margin XBIO (Xenetic Biosciences)|Operating Profit Rate SLRX|PPBT - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin